Buraczynska Monika, Bednarek-Skublewska Anna, Buraczynska Kinga, Ksiazek Andrzej
Department of Nephrology, Laboratory for DNA Analysis and Molecular Diagnostics, Medical University of Lublin, Dr K. Jaczewskiego 8, 20-954 Lublin, Poland.
Cytokine. 2008 Dec;44(3):361-5. doi: 10.1016/j.cyto.2008.10.001. Epub 2008 Nov 17.
Polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene (A-2518G) has been associated with functional effects. The aim of the present study was to assess the effect of this polymorphism on end-stage renal disease (ESRD) and cardiovascular disease (CVD) in hemodialyzed patients.
A total of 720 patients with ESRD treated with hemodialysis (450 patients with CVD) and 325 healthy control subjects were genotyped for the MCP-1 -2518 polymorphism by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) procedure.
There was a significant difference in genotype frequencies between entire group of hemodialyzed patients and controls (p<0.01). The odds ratio for the risk allele was 1.85, 95% CI 1.49-2.32 (p<0.01). Hemodialyzed patients were divided into subgroups with CVD (n=450) and without CVD (n=270). The G allele carriers occurred with significantly higher frequency in patients with CVD (62% vs. 38% in patients without CVD and 36% in controls). The odds ratio for the risk allele for patients with CVD vs. those without CVD was 2.17, 95% CI 1.71-2.79. There was no statistically significant difference in the distribution of MCP-1 genotypes between ESRD patients without CVD and healthy controls.
Our results demonstrate for the first time an association between the polymorphism in the regulatory region of the MCP-1 gene and susceptibility to CVD in hemodialyzed patients.
单核细胞趋化蛋白-1（MCP-1）基因（A-2518G）多态性与功能效应相关。本研究旨在评估该多态性对血液透析患者终末期肾病（ESRD）和心血管疾病（CVD）的影响。
采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法，对720例接受血液透析治疗的ESRD患者（其中450例患有CVD）和325例健康对照者进行MCP-1 -2518多态性基因分型。
血液透析患者全组与对照组的基因型频率存在显著差异（p<0.01）。风险等位基因的比值比为1.85，95%可信区间为1.49-2.32（p<0.01）。血液透析患者被分为患有CVD（n=450）和未患有CVD（n=270）的亚组。G等位基因携带者在患有CVD的患者中出现的频率显著更高（62%，未患CVD的患者中为38%，对照组中为36%）。患有CVD的患者与未患CVD的患者相比，风险等位基因的比值比为2.17，95%可信区间为1.71-2.79。未患CVD的ESRD患者与健康对照者之间MCP-1基因型分布无统计学显著差异。
我们的结果首次证明MCP-1基因调控区多态性与血液透析患者患CVD的易感性之间存在关联。
